NCT05105295

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With Human Immunodeficiency Virus Infected

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: China National Biotec Group Company Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of immunogenicity, safety and persistence of the subjects with HIV infected received the third dose of inactivated COVID-19 vaccine .

Detailed description

The subjects aged ≥18 years with HIV infected who have completed the schedule of two doses for 3 months recruited to receive a third dose of inactivated COVID-19 vaccine. Blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination. Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Conditions

• COVID-19
• HIV Infections

Interventions

Type	Name	Description
BIOLOGICAL	Inactivated COVID-19 vaccine	receive a third dose of inactivated COVID-19 vaccine

Timeline

• Start date: 2021-12-01
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2021-11-03
• Last updated: 2021-11-03

Locations

1 site across 1 country: China